Pharmafile Logo
Pharmafocus logo
Advanced Search

Onglyza

Showing 13 posts of 13 posts found.

FDA image

AZ and Takeda diabetes drugs get FDA safety update

April 15, 2015
Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, diabetes, saxagliptin

An FDA advisory committee has said that the labels of two type 2 diabetes drugs should be changed to warn …

News
Astrazeneca image

AstraZeneca diabetes drug could ‘significantly’ increase mortality

April 13, 2015
Research and Development, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, saxagliptin

AstraZeneca’s diabetes drug Onglyza may lead to a ‘significant increase’ in risk of death according to a new analysis from …

News

Scottish reforms proven to work says SMC

March 4, 2015
Sales and Marketing NHS, NICE, Onglyza, PACE, SMC, Scotland, anne lee, scottish

The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its processes have contributed to improved …

News
AZ image

AstraZeneca diabetes drug approved for use in Scotland

November 11, 2014
Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2

The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …

News
AstraZeneca image

AstraZeneca ‘rejects Pfizer bid’

April 22, 2014
Research and Development, Sales and Marketing AstraZeneca, Byetta, Onglyza, Pfizer, Soriot, merger

AstraZeneca has rebuffed a £60 billion bid from Pfizer, according to media reports. Both companies have declined to comment on …

News
Astrazeneca image

AstraZeneca ‘simplifies decision-making’

February 4, 2014
Sales and Marketing AstraZeneca, BMS, Byetta, Forxiga, Onglyza, diabetes

AstraZeneca has completed its $4.3 billion acquisition of Bristol-Myers Squibb’s diabetes business, giving the company control over several big-name brands …

News
BMS image

BMS sells diabetes stake to partner AstraZeneca

December 19, 2013
Sales and Marketing AstraZeneca, BMS, Forxiga, Onglyza, diabetes, komboglyze

AstraZeneca will buy out Bristol-Myers Squibb’s stake in its diabetes alliance in a potential $4.3 billion deal. AZ will pay …

News

BMS invests $15 million in Asian diabetes programme

June 11, 2012
Sales and Marketing Asia, BMS, China, India, Onglyza, diabetes

Bristol-Myers Squibb has invested $15 million into its ‘Together on Diabetes’ campaign in India and China. Together on Diabetes is …

News

Onglyza cleared for use with insulin

November 29, 2011
Sales and Marketing AstraZeneca, Merck, Onglyza, diabetes, insulin

European regulators have approved a licence extension for Bristol-Myers Squibb and AstraZeneca’s type II diabetes treatment Onglyza. The oral DPP-4 …

News

Onglyza expands European licence

March 4, 2011
Sales and Marketing AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes

European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that …

News

Five-year cardiovascular study planned for Onglyza

March 10, 2010
Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes

Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …

News

AZ-BMS launch Onglyza in Europe

October 19, 2009
Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes

 Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …

News

Onglyza approved in Europe

October 6, 2009
Sales and Marketing EU, Onglyza, diabetes

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026